News | December 05, 2021
Lupin and Biomm tie-up for pegfilgrastim in Brazil
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
The product will be commercialized from Unichem's Ghaziabad plant
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Subscribe To Our Newsletter & Stay Updated
